HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ephedra Sales Ban Gains Congressional Momentum Following Athlete’s Death

This article was originally published in The Tan Sheet

Executive Summary

Reps. John Sweeney (R-N.Y.) and Greg Walden (R-Ore.) announced plans to challenge ephedra's safety and address restrictions on the sale of the controversial ingredient following the death of professional baseball player Steve Bechler

You may also be interested in...

Nutraquest’s Chinery To Sue Orioles For Liability In Bechler Case

Nutraquest President Robert Chinery is seeking to shift any future liability and damages found against him for the death of Baltimore Orioles pitcher Steve Bechler to the Orioles organization

Xenadrine Safety Misrepresentations Alleged In Bechler Suit v. Cytodyne

Cytodyne's failure to adequately warn consumers about potential risks from taking ephedra-containing Xenadrine RFA-1 is the basis for a wrongful-death lawsuit filed by Orioles pitcher Steve Bechler's widow, Kiley Bechler, July 16

Ephedra Safety Taken Up By House Commerce Cmte, Cytodyne Sent Letter

The House Energy & Commerce Committee launched an investigation into the safety of ephedra Feb. 28 by sending letters to FDA Commissioner Mark McClellan, MD/PhD, and Cytodyne Technologies President Robert Chinery

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts